SCHEMBL5831393

SCHEMBL5831393

O=C(Cc1nnc(NS(=O)(=O)c2ccc(C(F)(F)F)cc2C(F)(F)F)s1)N1CCOCC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.46
KMT2A Q03164 1/20 0.42
P2RY1 P47900 1/20 0.41
HSD11B1 P28845 1/20 0.40
FKBP1A P62942 1/20 0.39
LMNA P02545 2/20 0.39
POLB P06746 1/20 0.39
ALDH1A1 P00352 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
MCOLN3 Q8TDD5 1/20 0.39
HPGD P15428 1/20 0.38
CASP1 P29466 1/20 0.38
HTT P42858 1/20 0.38
CASP7 P55210 1/20 0.38
HSD17B10 Q99714 1/20 0.38
ENPP2 Q13822 1/20 0.38
F2 P00734 1/20 0.37
CNR2 P34972 1/20 0.37
TSHR P16473 1/20 0.37
CCNC P24863 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3255071 0.86 HSD11B1 (0.49) KMT2AHSD11B1FKBP1ALMNAPOLB
SCHEMBL3608224 0.83 HSD11B1 (0.60) KMT2AHSD11B1FKBP1ALMNAPOLB
SCHEMBL5831585 0.83 SCN9A (0.43) KMT2AHSD11B1FKBP1ALMNAPOLB
SCHEMBL5830943 0.81 KMT2A (0.47) GAAKMT2AP2RY1HSD11B1LMNA
SCHEMBL6696959 0.81 LMNA (0.43) KMT2AHSD11B1FKBP1ALMNAPOLB
SCHEMBL5830627 0.80 HSD11B1 (0.52) GAAKMT2AHSD11B1POLBSMN1; SMN2
SCHEMBL5831627 0.79 GAA (0.42) GAAKMT2AHSD11B1FKBP1ALMNA
SCHEMBL6699924 0.79 ALDH1A1 (0.43) KMT2AFKBP1ALMNAPOLBALDH1A1
SCHEMBL5830794 0.78 GAA (0.45) GAAKMT2AHSD11B1POLBALDH1A1
SCHEMBL7091220 0.75 HSD11B1 (0.54) KMT2AHSD11B1LMNAPOLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030130258-A1 Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics BIOVITRUM AB (SE) 2003-07-10 US claimed
US-7074788-B2 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2006-07-11 US disclosed
US-20030130258-A1 Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics BIOVITRUM AB (SE) 2003-07-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130258-A1 Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics CPT1A, HSD11B1, CES1 GAA 265/4885KMT2A 2980/4885P2RY1 2047/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.